Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics. Issue 2 (December 2015) - Harvey, Christopher; Elpek, Kutlu; Duong, Ellen; Simpson, Tyler; Shu, ChengYi; Shallberg, Lindsey; Wallace, Matthew; Sathyanarayanan, Sriram; Mabry, Robert; Briskin, Michael; Michaelson, Jennifer; Gajewski, Thomas